SCOTUS hears "spirited" arguments in generic "flawed design" case
This article was originally published in SRA
Executive Summary
Lawyers argued vigorously on both sides at the US Supreme Court on 19 March over whether federal laws preempt those of a state when it comes to design defect injury claims involving a generic drug1.